HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goetz, C. G. Search for Related Content PubMed PubMed Citation Articles by Goetz, C. G.

Influence of COMT inhibition on levodopa pharmacology and therapy

From Rush University/Rush-Presbyterian St. Luke's Medical Center, Chicago, IL.

Address correspondence and reprint requests to Dr. Christopher G. Goetz, Department of Neurological Sciences, Rush University/Rush-Presbyterian St. Luke's Medical Center, 1725 W. Harrison Street, Chicago, IL 60612.

Abstract.

Catechol O-methyltransferase (COMT) is an important enzyme that is linked directly to therapy with levodopa. Considering the demonstrated mechanism of action and pharmacologic profiles of COMT inhibitors, it is reasonable to hypothesize that these agents would improve the disability associated with Parkinson's disease. Two basic classes of COMT inhibitors are being studied in patients with PD: those that act exclusively extracerebrally or peripherally (e.g., entacapone) and those that cross the blood-brain barrier (e.g., tolcapone). With COMT inhibition, greater peripheral bioavailability of levodopa occurs in humans without an enhancement of peak plasma levels. It is reasonable to suggest that COMT inhibition will be associated with prolonged effects of levodopa in PD, without increased peak dose toxicity in the form of dyskinesias and hallucinations.

This article has been cited by other articles:

				A. Storch, H. Blessing, M. Bareiss, S. Jankowski, Z. D. Ling, P. Carvey, and J. Schwarz Catechol-O-methyltransferase Inhibition Attenuates Levodopa Toxicity in Mesencephalic Dopamine Neurons Mol. Pharmacol., March 1, 2000; 57(3): 589 - 594. [Abstract] [Full Text]